Imagine creating a master key that can unlock and neutralize many different versions of a virus instead of just one. By giving horses a special mix of 8 different viral proteins, the project teaches their immune systems to produce a diverse army of antibodies. These are then refined into a safe medicine that can fight a whole family of coronaviruses, making it much harder for the virus to mutate and escape.
Monoclonal antibodies are prone to viral escape due to their narrow binding specificity and are often expensive to produce. There is a critical need for broad-spectrum, mutation-resilient antiviral therapies that can be stockpiled for rapid pandemic response.
A nanoparticle mosaic antigen and a hyperimmunization protocol that produces high-titer equine polyclonal F(ab’)2 fragments.
If you are a GMP manufacturer dealing with the high cost and risk of viral mutations in monoclonal therapies — this project developed a polyclonal F(ab’)2 production process that provides broader coverage and is more cost-effective.
If you are a health agency dealing with pandemic preparedness and the need for rapid response — this project developed a stockpiling strategy for GMP-grade fragments to enable immediate clinical deployment.
If you are a biotech firm dealing with low antibody titers in animal models — this project developed a hyperimmunization strategy using mosaic antigens to generate high-titer immunoglobulins.
Based on available project data, the polyclonal F(ab’)2 fragments are described as more cost-effective than monoclonal antibodies because they provide a multivalent approach.
Yes, the project utilizes the FBT manufacturing platform to produce GMP-grade therapeutic fragments intended for stockpiling and clinical deployment.
Based on available project data, specific licensing terms are not mentioned, but the project focuses on establishing a full EU-based production chain to ensure sovereignty.
The project is developing all necessary analytical methods early and collaborating with regulatory authorities to define the best approval strategy.
The project period runs from 2023-12-01 to 2027-11-30, aiming for a ready-to-use solution by the end of the term.
The consortium is highly commercially oriented with a 50% industry ratio, consisting of 6 partners across 4 countries. The presence of 3 industry players, including 2 SMEs and the coordinator FABENTECH (an SME), suggests a strong focus on translating the research into a marketable GMP-grade product rather than purely academic discovery.
Contact FABENTECH in France for details on GMP manufacturing and F(ab’)2 fragments.
Contact us to explore licensing opportunities for the mosaic antigen strategy.
